Skip to main content

BULLETIN OF STOMATOLOGY AND MAXILLOFACIAL SURGERY

For authors

BULLETIN OF STOMATOLOGY AND MAXILLOFACIAL SURGERY

Scientific and practical journal

1. Manuscript Submission

Manuscripts must be submitted electronically through the journal’s official manuscript submission system.

The journal accepts manuscripts prepared in Microsoft Word format (.doc or .docx).

By submitting a manuscript, the corresponding author confirms that:

  • The manuscript is original and has not been previously published, except in the form of an acceptable preprint, conference abstract, or other form disclosed to the editorial office.
  • The manuscript is not under consideration by another journal.
  • All authors have read and approved the submitted version.
  • All authors agree to its submission to JBSMFS.
  • The study has been conducted in accordance with applicable ethical standards.
  • All relevant funding sources and competing interests have been disclosed.
  • Permissions have been obtained for any copyrighted material reproduced in the manuscript.

Simultaneous submission of the same manuscript to more than one journal is not permitted.

2. Types of Manuscripts

JBSMFS considers the following categories of manuscripts:

Original Research Articles

Reports of original clinical, experimental, laboratory, epidemiological, observational, and other scientific investigations.

Recommended maximum length: 6,000 words, excluding references, tables, and figure legends.

Review Articles

Comprehensive and critical evaluations of current scientific evidence in dentistry, oral medicine, and maxillofacial surgery. Systematic reviews, meta-analyses, scoping reviews, and narrative reviews are considered.

Recommended maximum length: 8,000 words, excluding references, tables, and figure legends.

Systematic reviews and meta-analyses should follow the relevant PRISMA reporting guidelines.

Case Reports and Case Series

Reports describing clinically significant, unusual, or educational cases that provide relevant diagnostic, therapeutic, or scientific information.

Recommended maximum length: 4,000 words, excluding references and figure legends.

Case reports should follow the CARE reporting guidelines whenever applicable.

Short Communications and Clinical Reports

Brief reports presenting relevant preliminary findings, innovative clinical observations, or methodological developments.

The suitability and length of these submissions will be determined by the editorial office.

3. Manuscript Preparation and General Formatting

Manuscripts should be prepared in a clear, concise, and scientifically appropriate academic style.

The following formatting requirements should be followed:

  • File format: Microsoft Word (.doc or .docx).
  • Font: Times New Roman, 12-point.
  • Line spacing: 1.5.
  • Left margin: 3 cm.
  • Right margin: 1 cm.
  • Top and bottom margins: 2.5 cm.
  • Page numbers: bottom center.
  • Use SI units wherever applicable.
  • Define all abbreviations at their first occurrence.
  • Use internationally accepted scientific terminology.
  • Ensure consistency between the text, tables, figures, and references.

The manuscript should be organized into clearly identified sections.

4. Title Page

The title page should include:

  1. Full manuscript title.
  2. Full names of all authors.
  3. Institutional affiliations, including department, institution, city, and country.
  4. Identification of the corresponding author.
  5. Corresponding author’s institutional email address.
  6. ORCID identifiers, where available.
  7. A short running title, preferably no longer than 50 characters.
  8. Word count and number of tables and figures.

The title should be informative, concise, and accurately reflect the study design and principal subject.

Abbreviations should generally be avoided in the title.

For randomized controlled trials, systematic reviews, and meta-analyses, the study design should be identified in the title whenever appropriate.

5. Abstract and Keywords

All scholarly articles must include an accurate English-language abstract.

For manuscripts submitted in Armenian or Russian, the corresponding abstract in the original language may also be included.

The abstract should not exceed 300 words.

For original research articles, the abstract should be structured using the following headings:

  • Background: Brief scientific context and rationale.
  • Objective: The primary aim or hypothesis of the study.
  • Materials and Methods: Study design, setting, participants, sample size, interventions or measurements, and statistical methods.
  • Results: Principal findings, including relevant numerical data and statistical significance where appropriate.
  • Conclusion: The main interpretation and clinical or scientific relevance of the findings.

For review articles, the abstract should briefly describe the background, objective, methods of literature identification and selection, principal findings, and conclusion.

For case reports, the abstract should summarize the clinical background, case presentation, management, outcome, and clinical significance.

Clinical trial registration information should be included in the abstract whenever applicable.

Authors should provide 4–8 keywords, separated by semicolons. Keywords should reflect the main concepts of the manuscript. Where possible, authors are encouraged to use terms from the Medical Subject Headings (MeSH) vocabulary.

6. Main Text Structure

6.1. Introduction

The Introduction should provide the scientific background and rationale for the study.

Authors should:

  • Describe the current state of knowledge.
  • Summarize relevant and up-to-date literature.
  • Identify existing knowledge gaps or unresolved questions.
  • Explain the scientific or clinical importance of the research.
  • Clearly state the study objective and, where appropriate, the hypothesis.

The Introduction should be focused and should not contain an extensive review of unrelated literature.

6.2. Materials and Methods

The Materials and Methods section should provide sufficient detail to allow other researchers to understand and, where appropriate, reproduce the study.

Authors should clearly describe:

  • Study design and setting.
  • Study period and location.
  • Participant selection and eligibility criteria.
  • Sample size and its justification, where applicable.
  • Intervention, diagnostic procedures, and treatment protocols.
  • Materials, instruments, devices, and equipment used.
  • Outcome measures and assessment procedures.
  • Statistical methods and software used.
  • Ethical approval and informed consent, where applicable.

For clinical studies, authors should provide sufficient information about treatment allocation, randomization, blinding, follow-up, and participant withdrawals.

The number of participants initially enrolled, excluded, lost to follow-up, and included in the final analysis should be reported where applicable.

Statistical analyses should be described sufficiently to allow readers to evaluate the reliability of the findings. Authors are encouraged to report effect sizes, confidence intervals, and exact P values where appropriate, rather than relying exclusively on statistical significance.

6.3. Results

The Results section should present the findings clearly and objectively.

All relevant positive and negative findings should be reported.

Results should be organized logically and may be divided into subsections with appropriate headings.

Tables and figures should be used to clarify the findings without unnecessary duplication of information.

Numerical results should be presented accurately, with appropriate statistical indicators.

6.4. Discussion

The Discussion should interpret the principal findings in relation to the existing scientific literature.

Authors should address:

  • The principal findings of the study.
  • Comparison with previously published research.
  • Possible explanations for similarities or differences.
  • Scientific and clinical implications.
  • Strengths of the study.
  • Methodological limitations and potential sources of bias.
  • Implications for future research.

The Discussion should not simply repeat the Results section.

6.5. Conclusion

The Conclusion should provide a concise interpretation of the main findings in relation to the study objectives.

It should reflect the scientific contribution and potential clinical relevance of the research without making claims that are not supported by the presented data.

7. References

JBSMFS follows the Vancouver reference style.

References should be numbered consecutively in the order in which they first appear in the manuscript.

In-text citations should be indicated using Arabic numerals in square brackets.

Authors are responsible for ensuring that all references are accurate, complete, and directly relevant to the manuscript.

Where available, DOI information should be provided.

Authors are encouraged to cite original research articles and authoritative sources from peer-reviewed scientific journals.

Reference details, including author names, article titles, journal titles, publication years, volume numbers, issue numbers, page ranges, and DOI identifiers, must be checked carefully before submission.

References should be presented in Roman script. When citing publications originally published in non-Latin scripts, authors should provide transliterated bibliographic information and, where appropriate, indicate the original language.

8. Tables, Figures, and Illustrations

Tables and figures should be numbered consecutively according to their first appearance in the text.

Each table and figure must have a clear and informative title or legend.

Authors should:

  • Refer to all tables and figures in the main text.
  • Avoid unnecessary duplication of numerical information.
  • Define abbreviations and symbols in table footnotes or figure legends.
  • Submit figures in high-resolution electronic formats.
  • Provide photographic images at a resolution of at least 300 dpi.
  • Ensure that clinical photographs and radiological images do not reveal patient identity.

Preferred formats include TIFF, JPEG, PNG, and EPS, depending on the type of image.

Figures reproduced or adapted from previously published sources require appropriate permission and acknowledgement.

9. Authorship and Author Contributions

Authorship should be based on substantial intellectual and scientific contributions to the research.

JBSMFS encourages authors to follow the authorship recommendations of the International Committee of Medical Journal Editors (ICMJE).

All listed authors should meet the following criteria:

  1. Substantial contributions to the conception or design of the work, or the acquisition, analysis, or interpretation of data.
  2. Drafting the manuscript or critically revising it for important intellectual content.
  3. Final approval of the version to be published.
  4. Agreement to be accountable for all aspects of the work and to ensure that questions relating to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

All individuals who meet the authorship criteria should be included as authors.

Individuals who contributed to the work but do not meet the authorship criteria should be acknowledged appropriately, with their permission.

Honorary, guest, and ghost authorship are not acceptable.

A statement describing the specific contributions of each author should be included using the CRediT (Contributor Roles Taxonomy) framework whenever applicable.

The corresponding author is responsible for ensuring that all authors have approved the final manuscript and agreed to its submission.

Changes to the author list after submission require written agreement from all affected authors and approval by the Editor-in-Chief.

10. Funding Statement

All sources of financial support must be disclosed.

Authors should identify:

  • Funding organizations.
  • Grant numbers, where applicable.
  • The role of the funding organization in study design, data collection, analysis, interpretation, manuscript preparation, and the decision to submit the article.

If the research received no external financial support, authors should include the statement:

“This research received no external funding.”

11. Conflict of Interest

All authors must disclose any financial, personal, professional, or institutional relationships that could influence, or be perceived to influence, the research or its interpretation.

Potential conflicts include employment, consultancy, honoraria, grants, stock ownership, patents, and relationships with manufacturers of products or devices discussed in the manuscript.

If no competing interests exist, authors should include the following statement:

“The authors declare no conflicts of interest.”

All disclosures will be considered during editorial evaluation.

12. Data Availability Statement

Authors are encouraged to provide a Data Availability Statement indicating whether the data supporting the findings are available and, where applicable, how they can be accessed.

The statement should specify whether the data are:

  • Publicly available in a repository.
  • Available from the corresponding author upon reasonable request.
  • Included within the article or supplementary materials.
  • Restricted because of privacy, confidentiality, ethical, or legal considerations.

Authors must ensure that data sharing does not compromise participant confidentiality or violate ethical approval conditions.

13. Reporting Guidelines

Authors are encouraged to follow internationally recognized reporting guidelines appropriate to their study design.

Examples include:

  • CONSORT – randomized controlled trials.
  • STROBE – observational studies.
  • PRISMA – systematic reviews and meta-analyses.
  • PRISMA-ScR – scoping reviews.
  • CARE – case reports.
  • STARD – diagnostic accuracy studies.
  • ARRIVE – animal research.
  • SQUIRE – quality improvement studies.

Relevant reporting checklists and flow diagrams should be submitted as supplementary files when applicable.

14. Use of Artificial Intelligence Tools

Authors must disclose the use of generative artificial intelligence (AI) tools or AI-assisted technologies in the preparation of the manuscript when such tools have contributed to the development of the submitted content.

The disclosure should identify the tool and describe its role.

AI tools cannot be listed as authors because they cannot assume responsibility for the accuracy, originality, and integrity of the work.

Authors remain fully responsible for all submitted content, including the verification of references, data, statistical analyses, and statements generated or assisted by AI tools.

The use of AI tools for language editing, grammar correction, or improvement of readability should be disclosed when it constitutes a substantive contribution to manuscript preparation.

AI tools must not be used to fabricate, manipulate, or falsify research data, images, or scientific results.

15. Acknowledgments

Individuals who contributed to the research but do not meet the criteria for authorship may be acknowledged.

Their contributions should be described clearly, and their permission to be acknowledged should be obtained before submission.

Funding information should be reported separately in the Funding Statement.

16. Article Processing Charges (APC)

JBSMFS is a self-funded, open access journal. Article Processing Charges support editorial management, peer-review administration, DOI registration, typesetting, online publication, hosting, and digital archiving.

The current APC structure is as follows:

  • Authors affiliated with institutions in Armenia: 40,000 AMD (approximately USD 100).
  • Authors from low- and middle-income countries: USD 300.
  • Authors from high-income countries: USD 500.
  • Conference abstracts: USD 50.

APCs are requested only after a manuscript has been formally accepted.

An official invoice is issued together with the galley proof of the accepted article.

Publication proceeds after confirmation of payment.

Payment of an APC does not guarantee acceptance and has no influence on peer-review outcomes or editorial decisions.

Partial or full waivers may be considered in exceptional circumstances, including limited institutional funding, early-career researchers, students, or invited manuscripts.

Waiver requests should be submitted before or during peer review and are evaluated independently of editorial decisions.

17. Editorial and Publication Timeline

The journal aims to maintain an efficient and transparent editorial process.

The approximate processing times are:

  • Initial editorial screening: 7–10 days.
  • Peer-review process: 21–28 days.
  • Final editorial decision: approximately 28–42 days from submission, depending on the review process.
  • Publication after acceptance: approximately 10 days, subject to completion of revisions, author approval of proofs, and administrative requirements.

These periods are indicative and may vary depending on reviewer availability, manuscript complexity, and the time required for author revisions.

18. Final Submission Checklist

Before submitting a manuscript, authors should ensure that:

  • The manuscript falls within the scope of JBSMFS.
  • The work is original and is not under consideration elsewhere.
  • The manuscript follows the journal’s formatting requirements.
  • The title page contains complete author and affiliation information.
  • An English-language abstract and 4–8 keywords are included.
  • The manuscript contains all required sections.
  • References are formatted consistently in Vancouver style.
  • Tables and figures are numbered and cited in the text.
  • Ethical approval and informed consent statements are included where applicable.
  • Clinical trial registration information is provided where required.
  • Author contributions are clearly described.
  • Funding and competing interests are disclosed.
  • Data availability and AI-use statements are provided where applicable.
  • All authors have approved the final version.
  • Permissions for reproduced material have been obtained where necessary.